Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1998-08-17
2004-04-27
Shukla, Ram R. (Department: 1632)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388230
Reexamination Certificate
active
06727350
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to novel Toso proteins, nucleic acids and antibodies. The invention further relates to the use of bioactive agents such as Toso proteins, nucleic acids and antibodies capable of modulating Fas or tumor necrosis factor (“TNF”) receptor mediated apoptosis for the diagnosis and treatment of disease.
BACKGROUND OF THE INVENTION
Apoptosis or programmed cell death is an important homeostatic mechanism that maintains cell number, positioning, and differentiation. Several intracellular and intercellular processes are known to regulate apoptosis. One of the best characterized systems is initiated by the cell surface receptor, Fas (Apo-1/CD95), homologues of which initiate apoptosis in a wide range of organisms (Itoh, et al.,
Cell,
66:233-243 (1991); Yonehara, et al,
J. Exp. Med.,
169:1747-1756 (1989)). Clustering of the Fas cytoplasmic domain generates an apoptotic signal via the “death domain” (Itoh and Nagata,
J. Biol. Chem.,
268:10932-10937 (1993)). Several critical proteins that bind to the death domain or other domains within the cytoplasmic region have been identified using yeast two-hybrid and biochemical screens (Boldin, et al.,
J. Biol. Chem.,
270:7795-7798 (1995); Chinnaiyan, et al.,
Cell,
8145:505-512 (1995); Chu, et al.,
Proc. Natl. Acad. Sci. USA,
92:11894-11898 (1995); Okura, et al,
J. Immnunol.,
157:4277-4281 (1996); Sato, et al.,
Science,
268:411-415 (1995); Stanger, et al.,
Cell,
8145:513-523 (1995)).
Fas engagement by Fas ligand is capable of activating the interleukin-1&bgr; converting enzyme family of cysteine proteases (Caspases)—the proteolytic executors of apoptosis (Enari, et al.,
Nature,
375:78-81 (1995); Enari, et al.,
Nature,
380:723-726 (1996); Los, et al.,
Nature,
375:81-83 (1995); Tewari and Dixit,
J. Biol. Chem,
270:3255-3260 (1995)). Recent studies implicate caspase8 (MACH/FLICE/Mch5) as linking Fas receptor signaling to downstream caspases via its association with FADD/MORT1 (Boldin, et al., (1995); Chinnaiyan, et al., (1995); Boldin, et al., (1996); Fernandes-Alnemri, et al.,
Proc. Natl. Acad Sci. USA,
93:7464-7469 (1996); Muzio, et al.,
Cell,
85:817-827 (1996)). Several groups have reported that caspase-8 activation is inhibited by a cellular inhibitor, cFLIP/FLAME-1/1-FLICE (Irmler, et al.,
Nature,
388:190-195 (1997); Srinivasula, et al.,
J. Biol. Chem.,
272:18542-18545 (1997); Hu, et al.,
J. Biol. Chem.,
272:17255-17257 (1997)). Other proteins involved in Fas-mediated apoptosis include: (a) the Fas-activated serine/threonine kinase (FAST kinase), which is rapidly activated during Fas-mediated apoptosis; (b) acid sphingomyelinase, which produces ceramide, a pro-apoptotic signal that acts as a second messenger in several systems; and (c) Daxx, a novel protein that links Fas to the JNK stress kinase pathway (Cifone, et al.,
J. Exp. Med.,
180:1547-1552 (1994); Tian, et al.,
J. Exp. Med.,
182:865-874 (1995); Yang, et al.,
Cell,
89:1067-1076 (1997)). The exact role of these latter co-activators has yet to be fully defined.
A balance between life and programmed cell death signals in cells is likely to be governed by multiple interacting regulators that counteract apoptotic signals with appropriate anti-apoptotic signals. Imbalances in this regulation can result in wide variety of pathologies, including cancer and immune dysfunction and it is now clear that other polypeptides besides Fas contribute to disregulation of appropriately induced apoptosis. As an example, in many tumor cell lines Fas expression does not correlate with sensitivity to Fas-induced apoptosis, implying the existence of Fas-resistance protein (Richardson, et al.,
Eur. J. Immunol.,
24:2640-2645 (1994)). Also, in some types of cells, Fas-induced apoptosis requires protein synthesis inhibitors such as cycloheximide (Itoh and Nagata, (1993); Yonehara, et al., (1989)) and even in Fas-sensitive cells, protein synthesis inhibitors can play a synergistic role with cycloheximide (Itoh and Nagata, (1993)). These combined observations further suggest the existence of proteins capable of suppressing Fas-generated apoptotic signaling.
Additionally, in the course of a normal immune response, both cytotoxic T cell and NK cell activation can lead to Fas ligand (FasL) induction of apoptosis in target cells (Arase, et al.,
J. Exp. Med.,
181:1235-1238 (1995); Berke,
Cell,
81:9-12 (1995); Montel, et al.,
Cell Immunol.,
166:236-246 (1995)). Although both Fas and FasL are rapidly induced following T-cell activation, activated-T cells remain resistant to Fas-induced apoptosis for several days (Klas, et al.,
Int. Immunol.,
5:625-630 (1993); Owen-Schaub, et al.,
Cell Immunol.,
140:197-205 (1992)). Thus, a mechanism exists to shield newly activated T cells from the cytotoxicity of their own FasL expression. This is likely to be an important component of T cell activation processes and protection in lymph nodes, splenic germinal centers and other sites at which T cell activation results in apoptosis of target cells.
Described herein is the identification and characterization of a novel surface molecule, “Toso” which is a member of the immunoglobulin gene superfamily and which specifically inhibits Fas and TNF receptor family mediated apoptosis. The results demonstrate the existence of cell surface mediated signaling pathways that lead to down regulation of Fas-mediated apoptosis in certain cell types and suggest that activation of T cells suppresses internal signaling systems that might lead inappropriately to T cell-induced self-killing.
Accordingly, it is an object of the invention to provide Toso proteins and related molecules. It is a further object of the invention to provide recombinant nucleic acids encoding Toso proteins, and expression vectors and host cells containing the nucleic acid encoding the Toso protein. A further object of the invention is to provide methods for screening for antagonists and agonists of Toso.
SUMMARY OF THE INVENTION
In accordance with the objects outlined above, the present invention provides recombinant nucleic acids encoding a Toso protein that will hybridize under high stringency conditions to the nucleic acid sequence depicted in
FIG. 1
(SEQ ID NO:1) or its complement. Recombinant nucleic acids encoding Toso proteins that are at least about 70% identical to the amino acid sequence depicted in
FIG. 1
(SEQ ID NO:1) are also provided, as well as recombinant nucleic acid that is at least about 70% identical to the nucleic acid sequence depicted in
FIG. 1
(SEQ ID NO:1) or its complement.
In a further aspect, the invention provides expression vectors and host cells comprising the nucleic acids of the invention, and processes for producing a Toso protein comprising culturing the host cells under conditions suitable for expression of a Toso protein.
In an additional aspect, the invention provides Toso proteins, and antibodies that bind to Toso proteins.
Further provided are methods of modulating apoptosis in a cell comprising administering to the cell a recombinant nucleic acid encoding a Toso protein, and methods for treating an apoptosis related condition in a mammal comprising administering a recombinant nucleic acid encoding a Toso protein.
REFERENCES:
patent: 6114515 (2000-09-01), Wu et al.
patent: 0 905 238 (1999-03-01), None
patent: 99/25832 (1999-05-01), None
Clark TM et al. Pathology Oncology Research 5:3-15, 1999.*
Anderson WF. Nature 392 (SUPP): 25-30, 1998.*
Verma IM and Somia N. Nature 389: 239-242. 1997.*
Orkin SH and Motulsky AG, Report and Recommendations of the Panel to Assess the NIH investment in reserch on gene therapy, 1995.*
Russell et al. Principles of antibody therapy. British Medical Journal. 305:424-429, 1992.*
Mehrene t al. Monoclonal anti-body based therapy. Current Opinion in Oncology. 8:493-498, 1996.*
Itoh, et al., “The Polypeptide Encoded by the cDNA for human Cell Surface Antigen Fas Can Mediate Apoptosis,”Cell, 66:233-243 (1991).
Yonehara, et al., “A Cell-Killing Monoclonal Antibody (ANTI-Fas) to a Cell Surface Antigen Co-Downregulated with t
Hitoshi Yasumichi
Nolan Garry P.
Bozicevic Field & Francis LLP
Keddie James S.
Shukla Ram R.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Toso does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Toso, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Toso will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3266260